ArticleJournal of neural transmission (Vienna, Austria : 1996)2018
Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Cerebrospinal fluid biomarkers for diagnosis of Parkinson's disease: a systematic review and network meta-analysis.Journal of neurology · 2025Pooled it
- Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy.Annals of clinical and translational neurology · 2026Article
- Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP.Acta neuropathologica · 2026Article
- Magnetic Susceptibility and Area in the Subthalamic Nucleus Measured by QSM for Diagnosis of Progressive Supranuclear Palsy.Movement disorders clinical practice · 2025Article
- Differentiating Progressive Supranuclear Palsy and Corticobasal Syndrome: Insights from Cerebrospinal Fluid Biomarkers-A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Cerebrospinal fluid tau and disease progression in early Parkinson's disease: an 8-year longitudinal study.Journal of neurology · 2024Article
- Review
- A biological characterization of patients with postmenopausal Parkinson's disease.Journal of neurology · 2024Article
- Translation from Preclinical Research to Clinical Trials: Transdermal Drug Delivery for Neurodegenerative and Mental Disorders.Pharmaceutical research · 2024Review
- Neuropathological changes associated with aberrant cerebrospinal fluid p-tau181 and Aβ42 in Alzheimer's disease and other neurodegenerative diseases.Acta neuropathologica communications · 2024Article
- Striatal dopaminergic lesions contributed to the disease severity in progressive supranuclear palsy.Frontiers in aging neuroscience · 2022Article
- Effects of head trauma and sport participation in young-onset Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2021Article
- Design of an Innovative Methodology for Cerebrospinal Fluid Analysis: Preliminary Results.Sensors (Basel, Switzerland) · 2021Article
- How Comorbidity Reflects on Cerebrospinal Fluid Biomarkers of Neurodegeneration in Aging.Journal of Alzheimer's disease reports · 2021Article
- Weaker Braking Force, A New Marker of Worse Gait Stability in Alzheimer Disease.Frontiers in aging neuroscience · 2020Article
- Association between physical activity and dementia's risk factors in patients with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2019Article
- Diagnosis of neurodegenerative dementia: where do we stand, now?Annals of translational medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive Supranuclear Palsy (PSP) is a four-repeat tauopathy with high phenotypic and neuropathological variability, highlighting the urgent need for effective disease biomarkers. Quantitative analysis of cerebrospinal fluid (CSF) proteins reflecting pathological changes of CNS is currently used as biomarkers of multiple neurodegenerative disorders for both early differential diagnosis and prognostic clustering of patients. In this study, we thus assessed the clinical usefulness of a panel of CSF biomarker in PSP patients presenting with Richardson's Syndrome. CSF levels of 42-beta-amyloid, total-tau, phosphorylated-tau, and both 42-beta-amyloid/phosphorylated-tau and phosphorylated-tau/total-tau ratios were comparatively evaluated in 39 PSP patients, 31 patients with Parkinson's Disease (PD) and 58 gender-/age-matched healthy controls. Specific gold-standard clinical scores were obtained. Diagnostic accuracy and clinical correlates of each biomarker were measured with receiver operating curve analysis and Spearman's test/linear regression, respectively. In PSP, 42-beta-amyloid was lower than either controls or PD; total-tau and phosphorylated-tau were instead reduced compared to controls, but similar to PD. At the cut-off value of 623 pg/ml, 42-beta-amyloid significantly distinguished PSP from controls and PD. Likewise, phosphorylated-tau/total-tau ratio also supported differential diagnosis between PSP and PD (cut-off = 0.185). 42-beta-amyloid was inversely associated with PSP severity, as measured with PSP Rating Scale. Our study demonstrates that CSF 42-beta-amyloid is reduced in PSP patients, proportionally to clinical severity, thus suggesting a potential use as disease biomarker. Moreover, phosphorylated-tau/total-tau ratio resulted helpful in the early differential diagnosis between PSP and PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.